Type: Product
Name: Uracyst
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

(MKTW) Tribute Pharmaceuticals Reports Solid Second Quarter 2014 Results

Tribute Pharmaceuticals Reports Solid Second Quarter 2014 ResultsMILTON, ONTARIO--(Marketwired - Aug 11, 2014) - Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with ... [Published Scottrade - Aug 11 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Tribute Pharmaceuticals to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Monday, August 11, 2014

/ Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) will host a conference call and live webcast to discuss the results of the second quarter 2014, to be held Monday, August 11, 2014 at 11:00 AM Eastern Time.To participate in this ... [Published Individual.com - Aug 08 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Tribute Pharmaceuticals Canada Inc. Closes $30 Million Unit Financing

) -NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTribute Pharmaceuticals Canada Inc. ("Tribute" or the "Company") (TSX VENTURE:TRX)(OTCQB:TBUFF) , is pleased to announce that it has closed its previously ... [Published MarketWired - Jul 15 2014]


"We are pleased with our progress in the second quarter of 2014," said Rob Harris, President and CEO of Tribute. "Our domestic sales were up, Cambia(R) continues to grow and we licensed the exclusive Canadian rights to bilastine, a new treatment option that, upon approval, will compete in the $115 million Allergic Rhinitis and Urticaria Market. Also we began trading on the TSX Venture Exchange, giving us better access to the Canadian capital markets and Canadian investors."
...Each Unit consists of one common share and one-half of one common share purchase warrant (each, a " Warrant " and together, the " Warrants ") at a price per Unit of $0.70 (the " Offering Price ") for aggregate gross proceeds of $30,026,500. Each Warrant entitles the holder thereof to acquire one common share of the Company at a price per share of $0.90 for a period of 24 months following the issuance thereof."

More Content

All (3) | News (3) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
(MKTW) Tribute Pharmaceuticals Reports Solid Se... [Published Scottrade - Aug 11 2014]
Tribute Pharmaceuticals to Host Second Quarter ... [Published Individual.com - Aug 08 2014]
Tribute Pharmaceuticals Canada Inc. Closes $30 ... [Published MarketWired - Jul 15 2014]
Contact Us

Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.